The Future: Think performance enhancers are a problem now?
By David Epstein,
Sports Illustrated
| 03. 11. 2008
Welcome to the era of the genetically engineered superathlete
I am one of the most avid sports fans you'll find," Se-Jin Lee says. It's true. He'll watch anything. Basketball. Football. Fútbol.
Billiards on channel seven-hundred-whatever. As a graduate student in
the '80s Lee used to sit in his car in the driveway with the radio on
to listen to the games of faraway baseball teams. Even now, in his lab
at Johns Hopkins Medical School in Baltimore, he easily rattles off the
NCAA basketball tournament winners in order from 1964 to 2007. And,
like anyone who values fair competition these days, he's disturbed by
the issue of performance-enhancing drugs in sports.
Why, then, is
Lee working to usher in technology that will make even today's most
inventive doping methods look primitive? A professor of molecular
biology and genetics, the 49-year-old Lee studies genes that tell
muscles what to do -- genes that he knows how to change. As clever as
chemists are in altering steroid molecules to avoid detection (recall
BALCO's THG, a.k.a. "the Clear"), those designer drugs can be spotted
once antidoping agencies know what to look for...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...